Pfizer's November 3 Report Must Separate Pipeline Progress From Decline

Pfizer's November 3 report will test whether newer products can offset the decline of its pandemic-era business. The company has scheduled a third-quarter results call for 10 a.m. Eastern that day, with the performance report due the same morning.

The June quarter provided encouraging operating evidence. Revenue rose 3% as reported to $15.0 billion, or 1% on an operational basis. Excluding Comirnaty and Paxlovid, revenue increased 5% operationally. Products that Pfizer launched or acquired grew 18% operationally, led by medicines including Eliquis, Padcev, the Vyndaqel family and Lorbrena.

Reported and adjusted earnings told different stories. Pfizer posted a reported loss of $0.04 per share after recording $4.3 billion of non-cash intangible-asset impairments, while adjusted diluted earnings were $0.77 per share. The distinction is essential because neither measure should be silently substituted for the other.

Pfizer raised the midpoint of its 2026 revenue guidance to $61.5 billion, within a range of $60.5 billion to $62.5 billion, and kept adjusted diluted earnings guidance at $2.80 to $3.00. That outlook includes a $650 million acquired in-process research and development charge tied to the Innovent transaction, expected to reduce third-quarter adjusted earnings by about $0.10 per share.

The pipeline offers both opportunity and uncertainty. Pfizer's 25-valent pediatric pneumococcal vaccine candidate produced robust immune responses against all 25 target serotypes in Phase 2, including stronger responses against serotype 3 than Prevnar 20. The company said adverse events were balanced between groups and that it identified no related serious adverse events. Phase 3 studies are under way, but the product remains an investigational candidate rather than approved revenue.

The original analysis also cited a disappointing overall-survival result for sigvotatug vedotin in lung cancer. Pfizer's accessible event material confirms the Phase 3 presentation at ESMO, but it did not provide enough primary detail to reproduce the exact survival figures responsibly. Those figures are therefore not repeated here.

The stock's rerating depends on more than meeting a quarterly consensus estimate. Pfizer needs launched and acquired products to sustain double-digit growth, older-product declines to moderate and late-stage programs to demonstrate clinical value. November 3 can clarify the first two points; the pipeline will require separate trial results and regulatory decisions.